Xenetic Biosciences, Inc.
XBIO
Rank in Stocks
#30843
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily... Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Share Price
$1.80
Last synced: 2026-11-09
Market Cap
$4.21M
Change (1 day)
-3.91%
Change (1 year)
-30.06%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Xenetic Biosciences, Inc. (XBIO)
Category
Healthcare
EPS for Xenetic Biosciences, Inc. (XBIO)
EPS as of June 2026 TTM: $-1.19
According to Xenetic Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-1.19. At the end of 2025 the company had an EPS of $-1.58, an increase over its 2024 EPS of $-2.57.
EPS history for Xenetic Biosciences, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.19 | -24.68% |
| 2025 | $-1.58 | -38.52% |
| 2024 | $-2.57 | -5.17% |
| 2023 | $-2.71 | -39.64% |
| 2022 | $-4.49 | -16.70% |
| 2021 | $-5.39 | -68.37% |
| 2020 | $-17.04 | -69.53% |
| 2019 | $-55.92 | -42.10% |
| 2018 | $-96.58 | 94.01% |
| 2017 | $-49.78 | -94.31% |
| 2016 | $-875.41 | 146.36% |
| 2015 | $-355.34 | -14.77% |
| 2014 | $-416.91 | -85.30% |
| 2013 | $-2.84K | 35.52% |
| 2012 | $-2.09K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,415.97% |
US
|
|
| $-7.07 | 494.12% |
US
|
|
| $-5.29 | 344.54% |
AU
|
|
| $12.88 | -1,182.36% |
BE
|
|
| $21.56 | -1,911.76% |
NL
|
Questions about Xenetic Biosciences, Inc.'s earnings per share (EPS)
What is Xenetic Biosciences, Inc.'s earnings per share (EPS)?
Xenetic Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-1.19, as of Jun 2026.
What was Xenetic Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Xenetic Biosciences, Inc.'s earnings per share (EPS) was $-1.58, compared with $-2.57 in 2024.
How has Xenetic Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Xenetic Biosciences, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.58) and lowest in 2020 ($-17.04).
How does Xenetic Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Xenetic Biosciences, Inc.'s earnings per share (EPS) ($-1.19) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.